This opportunity is not yet open for proposals. Use this time to prepare — engaging early (capability statement, contacting the agency) can position you for the upcoming solicitation.
The Defense Health Agency is procuring LUTATHERA® and PLUVICTO™, which are radiopharmaceuticals used for treating certain types of cancer. The procurement is aimed at ensuring the availability of these critical treatments for eligible patients. Key requirements include compliance with safety and regulatory standards for medical products.
Get your fit score, win probability, and required capabilities.
This listing does not include downloadable attachments. The solicitation details may be in the description below.
Verify on SAM.govNo description available
Get matched to contracts like this daily
Free AI-powered contract matching for your business.